Literature DB >> 12644960

Atypical antipsychotics in the treatment of schizophrenia.

René Bridler1, Daniel Umbricht.   

Abstract

Over the last few years atypical antipsychotics have been used increasingly in the pharmacological treatment of schizophrenia. This review provides an overview of the pharmacological and clinical characteristics of atypical antipsychotics. In particular we discuss their efficacy in treating psychotic and negative symptoms as well as treatment-refractory patients. The most important side effects as well as their possible interactions are reviewed in detail. Recommendations for the clinical use are given.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12644960     DOI： 2003/05/smw-10003

Source DB:  PubMed          Journal:  Swiss Med Wkly        ISSN： 0036-7672            Impact factor:   2.193


  7 in total

Review 1.  Molecular profiling of antipsychotic drug function: convergent mechanisms in the pathology and treatment of psychiatric disorders.

Authors:  Elizabeth A Thomas
Journal:  Mol Neurobiol       Date:  2006-10       Impact factor: 5.590

Review 2.  Quetiapine. A review of its use in the management of schizophrenia.

Authors:  Susan M Cheer; Antona J Wagstaff
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

3.  The efficacy and safety of blonanserin compared with haloperidol in acute-phase schizophrenia: a randomized, double-blind, placebo-controlled, multicentre study.

Authors:  Esther Garcia; Marta Robert; Francesc Peris; Hiroshi Nakamura; Noriko Sato; Yoshikatsu Terazawa
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

4.  THE METABOLIC SYNDROME IN OUTPATIENTS WITH PSYCHOSIS: A COMPARATIVE STUDY BETWEEN LONG ACTING INJECTABLE OLANZAPINE AND RISPERIDONE.

Authors:  L Dehelean; A M Romosan; M M Manea; I Papava; M Andor; R S Romosan
Journal:  Acta Endocrinol (Buchar)       Date:  2019 Jul-Sep       Impact factor: 0.877

5.  Issues around the Prescription of Half Tablets in Northern Switzerland: The Irrational Case of Quetiapine.

Authors:  Samuel S Allemann; Delia Bornand; Balthasar Hug; Kurt E Hersberger; Isabelle Arnet
Journal:  Biomed Res Int       Date:  2015-10-11       Impact factor: 3.411

6.  Pomaglumetad Methionil (LY2140023 Monohydrate) and Aripiprazole in Patients with Schizophrenia: A Phase 3, Multicenter, Double-Blind Comparison.

Authors:  David H Adams; Lu Zhang; Brian A Millen; Bruce J Kinon; Juan-Carlos Gomez
Journal:  Schizophr Res Treatment       Date:  2014-03-19

7.  Overexpression of Insig-2 inhibits atypical antipsychotic-induced adipogenic differentiation and lipid biosynthesis in adipose-derived stem cells.

Authors:  Chien-Chih Chen; Li-Wen Hsu; Kuang-Tzu Huang; Shigeru Goto; Chao-Long Chen; Toshiaki Nakano
Journal:  Sci Rep       Date:  2017-09-07       Impact factor: 4.379
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.